Cost-Effectiveness of Apomorphine Sublingual Film as an “On-Demand” Treatment for “OFF” Episodes in Patients with Parkinson's Disease
# Background “On-demand” treatments approved in the United States (US) for “OFF” episodes in Parkinson’s disease (PD) include apomorphine hydrochloride injection (SC-APO), apomorphine sublingual film (APL), and levodopa inhalation powder (CVT-301). APL received US approval in 2020, and its cost-effe...
Saved in:
| Main Authors: | Andrew Thach, Noam Kirson, Miriam L. Zichlin, Ibrahima Dieye, Eric Pappert, G. Rhys Williams |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2021-11-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/jheor.2021.29488 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson’s disease and OFF episodes: post hoc analyses of a phase III, open-label study
by: Jan Kassubek, et al.
Published: (2025-06-01) -
Apomorphine in the treatment of Parkinson's disease: a review
by: Renata Ramina Pessoa, et al. -
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
by: J. Scott Andrews, et al.
Published: (2019-01-01) -
Abnormal EEG Effects of Acute Apomorphine Injection in 5xFAD Transgenic Mice Are Partially Normalized in Those Chronically Pretreated with Apomorphine: The Time–Frequency Clustering of EEG Spectra
by: Vasily Vorobyov, et al.
Published: (2024-10-01) -
Formulation and Characterization of Eplerenone Nanocrystal as Sublingual Fast-dissolving Film
by: Hawraa Kareem, et al.
Published: (2024-12-01)